QuidelOrtho reports Q3 2026 growth in Labs and Immunohematology outside China and launches a restructuring initiative targeting $80 million in annual savings by 2027.
On 2026-11-03 QuidelOrtho reported third quarter 2026 results showing growth in Labs and Immunohematology outside of China. It also announced a cost transformation and enterprise restructuring program expected to deliver over $80 million in annual savings in 2027, which supports earnings. The updated full-year 2026 guidance narrowed the prior range, but the excerpt does not give the specific figures, and the emphasis on growth outside China points to continued China pressure.
The program is expected to deliver over $80 million in annual savings in 2027.
The article cites growth in Labs and Immunohematology outside of China.
QuidelOrtho reported its third-quarter 2026 financial results, highlighting growth in its Labs and Immunohematology segments outside of China. The company also announced a new enterprise restructuring program aimed at generating over $80 million in annual savings by 2027.
The program is designed to improve operational efficiency and is expected to deliver over $80 million in annual savings by 2027.
The company reported growth in its Labs and Immunohematology segments, specifically in markets outside of China.